A look back at some of the year’s biggest milestones
2021 ends, it is a perfect time to look back at the year’s highlights and recognize the many accomplishments of our team, partners, and customers.
Setting a new standard for antibody discovery
We kicked off the year with a launch of a new Antibody Discovery Module in January 2021. This suite of specialized Apps accelerates and improves the selection of antibody candidates. We developed it in close collaboration with over 50 industry leaders to reduce the bottlenecks experienced by researchers in the field. Even more industry leaders agreed. Zai Lab began using the IGX Platform to implement Next Generation Sequencing (NGS) as an additional tool to optimize its antibody selection, as well as many other clients that we cannot disclose yet.
Later in the year, at Biologics UK, we unveiled an extension of the IGX Platform empowering life scientists to make accurate developability predictions for thousands of sequences at the same time. With the IGX-Annotate App, researchers can accurately predict exposed liabilities, configure their own liability penalties, and integrate developability data throughout their workflow.
Building partnerships to improve antibody and vaccine development
Inno4Vac kicked off in 2021 and ENPICOM joined this European public-private partnership to innovate vaccine development. We are proud to help increase the speed of crucial scientific breakthroughs in vaccine development.
Back in 2019, we began working with Viroclinics-DDL, a state-of-the-art CRO, on TCR repertoire sequencing (Rep-Seq) and analysis. In 2021, we continued this collaboration and received a joint MIT subsidy to improve antibody and vaccine discovery and development. Then in September we held a webinar on T and B cell receptor sequencing. If you missed it, you can still watch a replay of this informative presentation and Q&A session.
Facilitating knowledge sharing
As the world adjusted to life with COVID-19, we slowly began to meet in person again. But that doesn’t mean that 2021 wasn’t a year of digital collaboration and knowledge sharing. We connected with some prominent experts in the field and released several free webinars to promote a deeper understanding of Rep-Seq-related topics. You can still watch them on demand.
- Dr. Dmitriy M. Chudakov, CSO at MiLaboratories LLC, and Dr. Nicola Bonzanni, CSO at ENPICOM, had an in-depth discussion on what we can learn from B cells and antibody repertoires to advance cell and gene therapies. They highlighted recent advancements in B cell research and cutting-edge software solutions for analyzing antibody repertoires.
- We had the pleasure to speak with Prof. Gunilla Karlsson Hedestam of Karolinska Institute about the impact of Rep-Seq on antibody and vaccine research.
- Our very own Application Scientist, Piotr van Rijssel, presented at the Antibody Discovery, Selection and Screening digital week on de-risking antibody development by predicting exposed liabilities using high-throughput structural modeling.
Growing on all fronts
Gillian O’Halloran joined the team as COO in February. We also moved into a new, larger office space. We were ranked 8 among the fastest growing Dutch companies in the data science field. We’re still growing so be sure to check our current vacancies.
We are not content to look back. We look forward to ongoing growth in antibody discovery and Rep-Seq data analysis in 2022. Innovative, efficient drug discovery is more important than ever.
We thank all our customers, friends, and partners for a fruitful, eventful, and fun 2021. We wish you all the most wonderful holiday season and a prosperous and healthy New Year!
Stay in touch in 2022. Sign up for our newsletter.